Creative Commons source reading · Neuromuscular and peripheral nerve disorders
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Alex Molassiotis; Hui Lin Cheng; Violeta Lopez; Joseph S K Au; Alexandre Chan; Aishwarya Bandla; K T Leung; Y C Li; K H Wong; Lorna K P Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Raghav Sundar
Originally published in BMC cancer · 2019-02-08
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy. Patients and methods Multi-country multisite prospective longitudinal observational study. Patients were assessed before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament); patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies. Results In total, 343 patients were recruited in the cohort, providing 2399 observations. There was wide variation in CIPN prevalence rates using different assessments (14.2-53.4%). Prevalence of sensory neuropathy (and associated symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to 71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile.
Discussion
The current study is the largest and one of a few longitudinal assessments of CIPN (2399 observations) using a heterogeneous population that increases the generalizability of the results. It showed that prevalence was significantly different from measure to measure used, patient reported outcome measures (through quality of life scales) consistently showed much higher CIPN rates than clinician-based or objective measures, and with highest rates in patients receiving taxanes (primarily paclitaxel). Cumulative dose was not linked with higher CIPN prevalence, but time since starting chemotherapy was.
Conclusions
This study maps the development and progression of CIPN in patients receiving taxane- and platinum-based chemotherapy, showing distinct CIPN profiles. It shows a lower level of CIPN than previously reported with significant differences among different chemotherapy protocols and scales used to measure CIPN. It brings into question the sensitivity and/or appropriateness of scales currently used to measure CIPN. Nevertheless, CIPN is a clinical problem present even 1 year after treatments and needs careful clinical attention.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
